Arlete Aparecida Martins Coelho-Castelo

Arlete Aparecida Martins Coelho-Castelo

Auto-generated profile, based on publicly available information

Arlete Aparecida Martins Coelho-Castelo

Department of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2008 in BMC Immunology
Verified
Journal Article
Open access
PDF file
RRRogério S Rosada
Rogério S Rosada
Lucimara de la TorreLucimara de la Torre
Lucimara de la Torre
FFFabiani Frantz
Fabiani Frantz
ATAna Pf Trombone
Ana Pf Trombone
CZCarlos R. Zárate-Bladés
Carlos R. Zárate-Bladés
ACArlete Am Coelho-Castelo
Arlete Am Coelho-Castelo
Background: The greatest challenges in vaccine development include optimization of DNA vaccines for use in humans, creation of effective single-dose vaccines, development of delivery systems that do not involve live viruses, and the identification of effective new adjuvants. Herein, we describe a novel, simple technique for efficiently vaccinating mice against tuberculosis (TB). Our technique consists of a single-dose, genetic vaccine formulation of DNA-hsp65 complexed with cationic liposomes and administered intranasally.Results: We developed a novel and non-toxic formulation of cationic liposomes, in which the DNA-hsp65 vaccine was entrapped (ENTR-hsp65) or complexed (COMP-hsp65), and used to immunize mice by intramuscular or intranasal routes. Although both liposome formulations induced a typical Th1 pattern of immune response, the intramuscular route of delivery did not reduce the number of bacilli. However, a single intranasal immunization with COMP-hsp65, carrying as few as 25 μg of plasmid DNA, leads to a remarkable reduction of the amount of bacilli in lungs. These effects were accompanied by increasing levels of IFN-γ and lung parenchyma preservation, results similar to those found in mice vaccinated intramuscularly four times with naked DNA-hsp65 (total of 400 μg).Conclusion: Our objective was to overcome the significant obstacles currently facing DNA vaccine development. Our results in the mouse TB model showed that a single intranasal dose of COMP-hsp65 elicited a cellular immune response that was as strong as that induced by four intramuscular doses of naked-DNA. This formulation allowed a 16-fold reduction in the amount of DNA administered. Moreover, we demonstrated that this vaccine is safe, biocompatible, stable, and easily manufactured at a low cost. We believe that this strategy can be applied to human vaccines to TB in a single dose or in prime-boost protocols, leading to a tremendous impact on the control of this infectious disease.

20 October 2010 in BMC Biotechnology
Verified
Journal Article
Open access
PDF file
JLJulio Cc Lorenzi
Julio Cc Lorenzi
ATAna Pf Trombone
Ana Pf Trombone
CRCarolina D Rocha
Carolina D Rocha
LALuciana P Almeida
Luciana P Almeida
RLRicardo L Lousada
Ricardo L Lousada
ACArlete Am Coelho-Castelo
Arlete Am Coelho-Castelo
Background: mRNAs are highly versatile, non-toxic molecules that are easy to produce and store, which can allow transient protein expression in all cell types. The safety aspects of mRNA-based treatments in gene therapy make this molecule one of the most promising active components of therapeutic or prophylactic methods. The use of mRNA as strategy for the stimulation of the immune system has been used mainly in current strategies for the cancer treatment but until now no one tested this molecule as vaccine for infectious disease. Results: We produce messenger RNA of Hsp65 protein from Mycobacterium leprae and show that vaccination of mice with a single dose of 10 μg of naked mRNA-Hsp65 through intranasal route was able to induce protection against subsequent challenge with virulent strain of Mycobacterium tuberculosis. Moreover it was shown that this immunization was associated with specific production of IL-10 and TNF-alpha in spleen. In order to determine if antigen presenting cells (APCs) present in the lung are capable of capture the mRNA, labeled mRNA-Hsp65 was administered by intranasal route and lung APCs were analyzed by flow cytometry. These experiments showed that after 30 minutes until 8 hours the populations of CD11c+, CD11b+ and CD19+ cells were able to capture the mRNA. We also demonstrated in vitro that mRNA-Hsp65 leads nitric oxide (NO) production through Toll-like receptor 7 (TLR7). Conclusions: Taken together, our results showed a novel and efficient strategy to control experimental tuberculosis, besides opening novel perspectives for the use of mRNA in vaccines against infectious diseases and clarifying the mechanisms involved in the disease protection we noticed as well.

1 April 2003 in Gene Therapy
Verified
Journal Article
Open access
PDF file
KLK M Lima
K M Lima
SSS A Santos
S A Santos
VLValéria Marçal Felix de Lima
Valéria Marçal Felix de Lima
ACA A M Coelho-Castelo
A A M Coelho-Castelo
JRJ M Rodrigues
J M Rodrigues
CSC L Silva
C L Silva
The high incidence of tuberculosis around the world and the inability of BCG to protect certain populations clearly indicate that an improved vaccine against tuberculosis is needed. A single antigen, the mycobacterial heat shock protein hsp65, is sufficient to protect BALB/c mice against challenge infection when administered as DNA vaccine in a three-dose-based schedule. In order to simplify the vaccination schedule, we coencapsulated hsp65-DNA and trehalose dimicolate (TDM) into biodegradable poly(DL-lactide-co-glycolide) (PLGA) microspheres. BALB/c mice immunized with a single dose of DNA-hsp65/TDM-loaded microspheres produced high levels of IgG2a subtype antibody and high amounts of IFN-γ in the supernatant of spleen cell cultures. DNA-hsp65/TDM-loaded microspheres were also able to induce high IFN-γ production in bulk lung cells from challenged mice and confer protection as effective as that attained after three doses of naked DNA administration. This new formulation also allowed a ten-fold reduction in the DNA dose when compared to naked DNA. Thus, this combination of DNA vaccine and adjuvants with immunomodulatory and carrier properties holds the potential for an improved vaccine against tuberculosis.

1 July 2001 in Glycobiology
Verified
Journal Article
Open access
PDF file
ELElaine V. Lourenço
Elaine V. Lourenço
SPSandra R. Pereira
Sandra R. Pereira
VFVitor Marcel Faça
Vitor Marcel Faça
ACArlete A. M. Coelho-Castelo
Arlete A. M. Coelho-Castelo
JMJose Roberto Mineo
Jose Roberto Mineo
ACAdemilson Panunto Castelo
Ademilson Panunto Castelo
Host cell invasion by Toxoplasma gondii is a multistep process with one of the first steps being the apical release of micronemal proteins that interact with host receptors. We demonstrate here that micronemal protein 1 (MIC1) is a lactose-binding lectin. MIC1 and MIC4 were recovered in the lactose-eluted (Lac+) fraction on affinity chromatography on immobilized lactose of the soluble antigen fraction from tachyzoites of the virulent RH strain. MIC1 and MIC4 were both identified by N-terminal microsequencing. MIC4 was also identified by sequencing cDNA clones isolated from an expression library following screening with mouse polyclonal anti-60/70 kDa (Lac+ proteins) serum. This antiserum localized the Lac+ proteins on the apical region of T. gondii tachyzoites by confocal microscopy. The Lac+ fraction induced hemagglutination (mainly type A human erythrocytes), which was inhibited by β-galactosides (3 mM lactose and 12 mM galactose) but not by up to 100 mM melibiose (α-galactoside), fucose, mannose, or glucose or 0.2 mg/ml heparin. The lectin activity of the Lac+ preparation was attributed to MIC1, because blotted MIC1, but not native MIC4, bound human erythrocyte type A and fetuin. The copurification of MIC1 and MIC4 may have been due to their association, as reported by others. These data suggest that MIC1 may act through its lectin activity during T. gondii infection.

4 November 2004 in Gene Therapy
Verified
Journal Article
Open access
PDF file
CSC L Silva
C L Silva
VBVania Luiza Deperon Bonato
Vania Luiza Deperon Bonato
ACA A M Coelho-Castelo
A A M Coelho-Castelo
Ana Olívia De SouzaAna Olívia De Souza
Ana Olívia De Souza
SSS A Santos
S A Santos
JRJ M Rodrigues
J M Rodrigues
Tuberculosis (TB) remains a threat for public health, killing around 3 million people a year. Despite the fact that most cases can be cured with antibiotics, the treatment is long and patients relapse if chemotherapy is not continued for at least 6 months. Thus, a better characterization of the working principles of the immune system in TB and identification of new immunotherapeutic products for the development of shorter regimens of treatment are essential to achieve an effective management of this disease. In the present work, we demonstrate that immunotherapy with a plasmid DNA encoding the Mycobacterium leprae 65 kDa heat-shock protein (hsp65) in order to boost the efficiency of the immune system, is a valuable adjunct to antibacterial chemotherapy to shorten the duration of treatment, improve the treatment of latent TB infection and be effective against multidrug-resistant bacilli (MDR-TB). We also showed that the use of DNA-hsp65 alone or in combination with other drugs influence the pathway of the immune response or other types of inflammatory responses and should augment our ability to alter the course of immune response/inflammation as needed, evidencing an important target for immunization or drug intervention.

2 August 2004 in Immunology
Verified
Journal Article
Open access
PDF file
VBVania Luiza Deperon Bonato
Vania Luiza Deperon Bonato
EGE. D. C. Gonçalves
E. D. C. Gonçalves
ESE. G. Soares
E. G. Soares
RJR. R. Santos Júnior
R. R. Santos Júnior
ASA. Sartori
A. Sartori
CSC. L. Silva
C. L. Silva
Summary: A DNA vaccine based on the heat‐shock protein 65 Mycobacterium leprae gene (pHSP65) presented a prophylactic and therapeutic effect in an experimental model of tuberculosis. In this paper, we addressed the question of which protective mechanisms are activated in Mycobacterium tuberculosis‐infected mice after immune therapy with pHSP65. We evaluated activation of the cellular immune response in the lungs of infected mice 30 days after infection (initiation of immune therapy) and in those of uninfected mice. After 70 days (end of immune therapy), the immune responses of infected untreated mice, infected pHSP65‐treated mice and infected pCDNA3‐treated mice were also evaluated. Our results show that the most significant effect of pHSP65 was the stimulation of CD8+ lung cell activation, interferon‐γ recovery and reduction of lung injury. There was also partial restoration of the production of tumour necrosis factor‐α. Treatment with pcDNA3 vector also induced an immune stimulatory effect. However, only infected pHSP65‐treated mice were able to produce significant levels of interferon‐γ and to restrict the growth of bacilli.